Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Pemvidutide also aced key secondary trial endpoints, including the proportion of patients with zero heavy drinking days in the final weeks of the study, the percentage of days with alcohol abstinence and serum phosphatidyl ethanol levels, a biomarker of alcohol intake
A 20-week bi-weekly dose escalation phase preceded maintenance
It has recently been shown that a PEGylated GLP-1R/GcgR co-agonist could restore leptin sensitivity in DIO mice chronically maintained on a high-fat diet [73], and this may constitute one of the inherent weight-lowering actions of the co-agonist
Wegovy is FDA-approved for weight loss and dosed up to 2.4 mg per week
This combination of a manageable safety profile and an ethical trial design that prioritizes patient outcomes is encouraging for future clinical adoption and real-world application
US$ 23.95
US$ 28.23
US$ 28.47
